{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:58:54Z","timestamp":1790369934640,"version":"4.1.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>The therapeutic goal in multiple myeloma (MM) is changing from long-term disease control to a potential cure. While anti-CD38-containing quadruplets have improved outcomes, relapses continue to occur in many patients. In recent years, advancements in immunotherapy have fundamentally changed this paradigm. Bispecific antibodies (BsAbs) and chimeric antigen receptor T-cells (CAR T-cells) have deepened responses and achieved sustained MRD negativity in an unprecedented way, raising the possibility of curing MM in a subset of patients. Recently, the International Myeloma Society (IMS) reached a consensus and discussed a framework to define cure. This review examines how novel immunotherapies are redefining frontline strategies in newly diagnosed MM (NDMM) and attempts to summarize how BsAbs, CAR T-cells, and cereblon E3 ligase modulators (CELMoDs) can be integrated into induction, consolidation, and maintenance phases. It also discusses the evolving role of autologous stem cell transplant (ASCT) in the immunotherapy era and MRD-guided treatment and discontinuation strategies. Together, this review attempts to provide a roadmap to fulfill the criteria for cure.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000853","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:01:06Z","timestamp":1790366466000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Toward a Cure in Multiple Myeloma: Redefining Induction Therapy and the Role of Autologous Stem Cell Transplant"],"prefix":"10.1097","volume":"32","author":[{"given":"Advait","family":"Joshi","sequence":"first","affiliation":[{"name":"Center for Multiple Myeloma, Mass General Brigham Cancer Institute"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Puliafito","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Mass General Brigham Cancer Institute"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana D.","family":"Cirstea","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Mass General Brigham Cancer Institute"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Branagan","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Mass General Brigham Cancer Institute"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua N.","family":"Gustine","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Mass General Brigham Cancer Institute"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajib","family":"Shome","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Mass General Brigham Cancer Institute"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Panaroni","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Mass General Brigham Cancer Institute"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Mass General Brigham Cancer Institute"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Mass General Brigham Cancer Institute"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9]]},"reference":[{"key":"R1-20260925","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"R2-20260925","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"R3-20260925","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"key":"R4-20260925","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41408-026-01461-7","article-title":"Toward a cure for multiple myeloma within a decade","volume":"16","author":"Mohty","year":"2026","journal-title":"Blood Cancer J"},{"key":"R6-20260925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"Van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"R7-20260925","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"R8-20260925","first-page":"1","article-title":"Incorporating the next generation of immunotherapies into the treatment of multiple myeloma","volume":"Featured Online Content","author":"Miller","year":"2026","journal-title":"J Natl Compr Canc Net"},{"key":"R9-20260925","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"The Lancet"},{"key":"R10-20260925","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"R11-20260925","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1158\/1078-0432.CCR-24-1872","article-title":"FDA approval summary: teclistamab\u2013A bispecific CD3 T-cell engager for patients with relapsed or refractory multiple myeloma","volume":"30","author":"Baines","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R12-20260925","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"R13-20260925","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"suppl","key":"R14-20260925","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies","volume":"41","author":"Nooka","year":"2023","journal-title":"J Clin Oncol"},{"key":"R15-20260925","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"R16-20260925","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"key":"R18-20260925","first-page":"1","article-title":"Teclistamab in multiple myeloma with one to three previous lines of therapy","volume":"Online ahead of print","author":"Touzeau","year":"2026","journal-title":"N Engl J Med"},{"issue":"suppl","key":"R19-20260925","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2024.42.16_suppl.7506","article-title":"Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM)","volume":"42","author":"Touzeau","year":"2024","journal-title":"J Clin Oncol"},{"key":"R20-20260925","doi-asserted-by":"crossref","first-page":"(3)1","DOI":"10.1200\/EDBK-25-473316","article-title":"Current and future directions of immunotherapies in multiple myeloma","volume":"45","author":"Biltibo","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"supplement 1","key":"R22-20260925","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1182\/blood-2025-367","article-title":"A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 teclille trial, cohort a","volume":"146","author":"Manier","year":"2025","journal-title":"Blood"},{"key":"R24-20260925","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-026-01802-w","article-title":"Advances in multiple myeloma: key updates from the ASH 2025 meeting","volume":"19","author":"Naing","year":"2026","journal-title":"J Hematol Oncol"},{"issue":"suppl","key":"R27-20260925","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2025.43.16_suppl.7504","article-title":"Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: initial results from MagnetisMM-6 part 1","volume":"43","author":"Quach","year":"2025","journal-title":"J Clin Oncol"},{"key":"R28-20260925","first-page":"1","article-title":"Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial","volume":"2026","author":"Raab","year":"2026","journal-title":"Nat Med"},{"issue":"supplement 1","key":"R31-20260925","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2025-697","article-title":"Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: initial results from the window of opportunity Phase 1\/2 LINKER-MM4 trial","volume":"146","author":"Orlowski","year":"2025","journal-title":"Blood"},{"issue":"supplement 1","key":"R32-20260925","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1182\/blood-2025-2288","article-title":"A Phase 2\/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"146","author":"Manier","year":"2025","journal-title":"Blood"},{"issue":"suppl","key":"R34-20260925","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.1200\/JCO.2025.43.16_suppl.7532","article-title":"Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): updated results from the CC-220-MM-001 trial","volume":"43","author":"White","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"R36-20260925","doi-asserted-by":"crossref","first-page":"7553","DOI":"10.1200\/JCO.2025.43.16_suppl.7553","article-title":"Carfilzomib, iberdomide, and dexamethasone (KID) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated results from phase 1\/2 study","volume":"43","author":"Biran","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"R38-20260925","doi-asserted-by":"crossref","first-page":"7514","DOI":"10.1200\/JCO.2026.44.16_suppl.7514","article-title":"Efficacy and safety of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma","volume":"44","author":"Kapoor","year":"2026","journal-title":"J Clin Oncol"},{"issue":"supplement 1","key":"R40-20260925","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/blood-2025-248","article-title":"A phase 2 trial of abbreviated fixed-duration (default 4 cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)","volume":"146","author":"Kazandjian","year":"2025","journal-title":"Blood"},{"key":"R41-20260925","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/17474086.2024.2382897","article-title":"Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide","volume":"17","author":"Liu","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"R42-20260925","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"key":"R43-20260925","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"R44-20260925","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u2265 5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"R45-20260925","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease\u2013guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl","key":"R46-20260925","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2026.44.16_suppl.7504","article-title":"Impact of sustained MRD negativity for up to 5 years on long-term outcome of transplant-eligible newly diagnosed multiple myeloma patients enrolled in the randomized phase 2 FORTE trial","volume":"44","author":"D\u2019Agostino","year":"2026","journal-title":"J Clin Oncol"},{"key":"R50-20260925","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood.2024026230","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial","volume":"146","author":"Perrot","year":"2025","journal-title":"Blood"},{"key":"R56-20260925","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"R57-20260925","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"R58-20260925","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"R59-20260925","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"issue":"suppl","key":"R60-20260925","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"key":"R62-20260925","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl","key":"R63-20260925","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1200\/JCO.2025.43.16_suppl.7539","article-title":"Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed\/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses","volume":"43","author":"Sidana","year":"2025","journal-title":"J Clin Oncol"},{"key":"R64-20260925","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V122.21.406.406","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 trial","volume":"122","author":"Attal","year":"2013","journal-title":"Blood"},{"key":"R65-20260925","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"R66-20260925","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.clml.2018.05.019","article-title":"Treatment intensification with autologous stem cell transplantation and lenalidomide maintenance improves survival outcomes of patients with newly diagnosed multiple myeloma in complete response","volume":"18","author":"Mina","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R67-20260925","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"key":"R69-20260925","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1016\/S2352-3026(26)00011-6","article-title":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial","volume":"13","author":"Dytfeld","year":"2026","journal-title":"Lancet Haematol"},{"key":"R71-20260925","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"key":"R75-20260925","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-024-01156-x","article-title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"key":"R80-20260925","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S2152-2650(23)01663-4","article-title":"P-045 Early treatment with bispecific T-cell redirectors (teclistamab or talquetamab) + daratumumab in newly diagnosed high-risk multiple myeloma: an open-label, phase 2, pilot study (GEM-TECTAL)","volume":"23","author":"Rodriguez-Otero","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl","key":"R82-20260925","doi-asserted-by":"crossref","first-page":"e4258276","DOI":"10.1097\/01.HS9.0000975288.42582.76","article-title":"PB2131: MagnetisMM-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma","volume":"7","author":"Manteca","year":"2023","journal-title":"Hemasphere"},{"key":"R83-20260925","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/ejh.14121","article-title":"Teclistamab-cqyv in multiple myeloma","volume":"112","author":"Martino","year":"2024","journal-title":"Eur J Haematol"},{"issue":"supplement 1","key":"R84-20260925","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2025-101","article-title":"Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: an update from the phase 2 EMN26 trial","volume":"146","author":"van de Donk","year":"2025","journal-title":"Blood"},{"key":"R85-20260925","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1182\/blood.2024027686","article-title":"Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma","volume":"145","author":"Terpos","year":"2025","journal-title":"Blood"},{"key":"R86-20260925","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/ajh.70339","article-title":"Integrating recent evidence and expert perspectives into the management of multiple myeloma: consensus recommendations from the 2025 Bridging the Gaps Conference","volume":"101","author":"Chari","year":"2026","journal-title":"Am J Hematol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:01:13Z","timestamp":1790366473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000853","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-07-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}